Preclinical evaluation of a chimpanzee adenovirus vector expressing a pre-fusion Spike (BV-AdCoV-1) SARS-CoV-2 intranasal vaccine candidate in golden Syrian hamsters

Authors

Shen Wang¹, Ting Mu¹, Ping Zhao¹, Guillaume Fichet², Karine Mouchain², Michel Klein¹, Ke Wu¹, Nicolas Legrand²

¹ BravoVax, Wuhan, China; , ² Oncodesign Services, Villebon-sur-Yvette, France

Introduction

Since the onset of SARS-CoV-2 pandemics in early 2020, Oncodesign Services has developed and established multiple in vitro and in vivo preclinical solutions for the evaluation of new therapeutic options. Vaccine delivery at the mucosal level is an attractive strategy to induce potent, local immune responses to protect the lower and upper respiratory tracts against infection. Mucosal vaccine delivery is noninvasive, convenient, easily accessible and thus, represents a promising approach to facilitate mass immunization, overcome vaccine hesitancy and achieve herd immunity.

In this work, we have evaluated the efficacy of the BRAVOVAX vaccine candidate BV-AdCoV-1 in the golden Syrian hamster model, using intranasal (IN) delivery route.

Read the poster